Am J Transplant, Volume 18, Suppl 3 Archives - Page 133 of 211 - ATC Abstracts

2018 American Transplant Congress
Steroid Sparing Maintenance Immunosuppression is Associated with Decreased Mortality after Simultaneous Liver Kidney Transplantation
S. Weeks, X. Luo, C. Song, L. Pote, A. Gurakar, F. Navqi, B. Philosophe, A. Cameron, N. Desai, S. Ottmann, D. Segev, J. Garonzik Wang.
Johns Hopkins, Baltimore, MD.
Purpose: Significant variation in maintenance immunosuppression (mIS) regimens has been described between transplant centers for simultaneous liver kidney (SLK) transplant recipients; we sought to describe…
2018 American Transplant Congress
The Protective Effect of Multivisceral Transplantation on Intestinal Allograft Rejection – Its Correlation with T-Cell Macrochimerism from a Long-Term Prospective Study
P. Liou,¹ M. Martinez,¹ J. Fu,² M. Velasco,¹ A. Griesemer,¹ S. Lobritto,¹ J. Vittorio,¹ S. Ravella,¹ B. Levin,³ J. Emond,¹ M. Sykes,² T. Kato.¹
¹Center for Liver Disease and Transplantation, Columbia University, New York, NY; ²Columbia Center for Translational Immunology, Columbia University, New York, NY; ³Department of Biostatistics, Columbia University, New York, NY.
Objective Graft rejection remains the crux of intestinal transplantation. Although liver-inclusive grafts appear to be protective, the mechanism remains unknown. We hypothesize that T-cell macrochimerism…
2018 American Transplant Congress
Senolytic Drug Treatment Attenuates mtDNA-Mediated Inflammatory Injury in Old Donors and Prolongs Cardiac Allograft Survival
K. Minami,¹ M. Seyda,¹ T. Heinbokel,¹ Y. Nian,¹ M. Quante,¹ G. Liu,¹ R. Abdi,² T. Tchkonia,³ J. Kirkland,³ A. Elkhal,¹ S. Tullius.¹
¹Transplant Surgery Division, Department of Surgery, Brigham and Women's Hospital, Boston, MA; ²Transplantation Research Center, Brigham and Women's Hospital, Boston; ³Robert and Arlene Kogod Center on Aging, Mayo Clinic College of Medicine, Rochester, MN.
Introduction: Solid organ transplantation has seen a increase in the utilization of older organs. Here, we investigate how aging-associated kinetics of damage associated molecular patterns…
2018 American Transplant Congress
Outcomes Analysis of Liver Transplantation Combined with Neoadjuvant Therapy in Patients with Unresectable Locally-Advanced Cholangiocarcinoma
M. Wong,¹ J. Kim,¹ C. Eriksen,¹ T. Pearson,¹ J. Robbins,² B. George,³ M. Zimmerman,¹ J. Hong.¹
¹Div. of Transplant Surgery, Medical College of Wisconsin and Froedtert Hospital (MCW & FH), Milwaukee, WI; ²Dept. of Radiation Oncology, MCW & FH, Milwaukee, WI; ³Div. of Hematology/Oncology, MCW & FH, Milwaukee, WI.
Objective: Liver transplantation (LT) combined with neoadjuvant chemoradiation (NCR) in well-selected patients with unresectable cholangiocarcinoma (CCA) achieves excellent long-term recurrence-free survival. Current criteria for NCR-LT…
2018 American Transplant Congress
Disparity in Access to Kidney Allograft Offers among HIV+ Transplant Candidates
J. Cohen,¹ J. Locke,² B. Shelton,² R. Reed,² P. MacLennan,² D. Sawinski.¹
¹Renal Division, University of Pennsylvania, Philadelphia, PA; ²Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, AL.
Background: Despite having a demonstrated survival benefit with kidney transplantation, patients with chronic viral infections, such as HCV or HIV, face many barriers to transplantation,…
2018 American Transplant Congress
Disparate Candidate Selection Practices and Substantial Use of Low KDPI Kidneys in Combined Heart-Kidney and Liver-Kidney Transplantation, 2012-2016
R. Steiner,¹ J. Halldorson.²
¹Transplant Nephrology, University of California at San Diego School of Medicine, San Diego, CA; ²Transplant Surgery, Sharp Memorial Hospital/Balboa Nephrology, San Diego, CA.
Transplant professionals have struggled to formulate defensible standards for combined heart-kidney and liver-kidney transplantation (HKTs and LKTs). In these recipients, recovery of native renal function…
2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
C-.H. Cheng,^1,2 C-.F. Lee,^1,2 G. Furtmüller,³ B. Oh,³ C. Patel,¹ Y-.C. Lo,¹ M. Fryer,³ G. Brandacher,³ J. Powell.¹
¹Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, New Taipei City, Taiwan; ³Vascularized Composite Allotransplantation Laboratory, Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…
2018 American Transplant Congress
B Cell Immune Repertoire Sequencing Identifies Pre-Transplant Rejection Risk
S. Pineda,^1,2 T. Sigdel,¹ J. Liberto,¹ K. Roskin,³ S. Robin,³ M. Sirota,² M. Sarwal.¹
¹Surgery, UCSF, SF; ²ICHS, UCSF, SF; ³Pathology, Stanford, Stanford.
Background: The diversity of the B cell immune repertoire may drive humoral injury and rejection in organ transplantation (tx).Methods: We utilized advances in next-generation sequencing…
2018 American Transplant Congress
Recipient HO-1 Deficiency Decreases Post-Transplant Graft HO-1 Expression and Exacerbates Liver Transplant Damage
S. Kageyama,¹ K. Nakamura,¹ T. Ito,¹ A. Aziz,¹ B. Ke,¹ R. Sossa,² E. Reed,² F. Kaldas,¹ R. Busuttil,¹ J. Kupiec-Weglinski.¹
¹Surgery, Liver Transplantation, UCLA, Los Angeles, CA; ²Pathology, UCLA, Los Angeles, CA.
Many preclinical studies on protective functions of heme oxygenase-1 (HO-1; hsp32) in orthotopic liver transplantation (OLT) have encouraged application of HO-1 inducing regimens in clinical…
2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
N. Bath, S. Parajuli, G. Leverson, M. Jorgenson, J. Fose, T. Ellis, D. Kaufman, A. Djamali, R. Redfield.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…